208 related articles for article (PubMed ID: 15197663)
21. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
Bartlett JM; Nielsen TO; Gao D; Gelmon KA; Quintayo MA; Starczynski J; Han L; Burnell MJ; Levine MN; Chen BE; Shepherd LE; Chapman JW;
Br J Cancer; 2015 Sep; 113(5):722-8. PubMed ID: 26284338
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
23. Emerging nontaxane therapies for metastatic breast cancer.
O'Regan R
Clin Adv Hematol Oncol; 2012 Mar; 10(3):187-9. PubMed ID: 22402428
[No Abstract] [Full Text] [Related]
24. Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis.
Feng QJ; Zhang F; Huang XY; Wu ZX
Pathol Oncol Res; 2014 Jan; 20(1):179-84. PubMed ID: 23980023
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of C-7, C-9 and C-10 modified taxane analogues from 1-deoxybaccatin VI.
Xie C; Cui Y; Li L; Zhang M; Liu H; Lin H
Bioorg Med Chem; 2020 Nov; 28(21):115736. PubMed ID: 33065439
[TBL] [Abstract][Full Text] [Related]
26. Taxane-induced scleroderma.
Itoh M; Yanaba K; Kobayashi T; Nakagawa H
Br J Dermatol; 2007 Feb; 156(2):363-7. PubMed ID: 17223879
[TBL] [Abstract][Full Text] [Related]
27. Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
Gehrmann M
Curr Opin Investig Drugs; 2006 Jun; 7(6):574-80. PubMed ID: 16784029
[TBL] [Abstract][Full Text] [Related]
28. Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens.
Cadoo K; Lowery M; McCaffrey J
Clin Breast Cancer; 2009 Nov; 9(4):262. PubMed ID: 19933084
[No Abstract] [Full Text] [Related]
29. A case of taxane-induced scleroderma: a different expression profile of Fli1 proteins in dermal fibroblasts and microvascular endothelial cells compared with systemic sclerosis.
Takahashi T; Asano Y; Ichimura Y; Taniguchi T; Kogure A; Tamaki Z; Takekoshi T; Sugaya M; Sato S
Br J Dermatol; 2011 Jun; 164(6):1393-5. PubMed ID: 21299546
[No Abstract] [Full Text] [Related]
30. No flow pattern on indocyanine green lymphography in breast cancer patients undergoing taxane-based chemotherapy.
Tokumoto H; Akita S; Nakamura R; Yamamoto N; Kubota Y; Mitsukawa N
J Plast Reconstr Aesthet Surg; 2020 Aug; 73(8):1575-1592. PubMed ID: 32269010
[No Abstract] [Full Text] [Related]
31. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
32. Larotaxel: broadening the road with new taxanes.
Metzger-Filho O; Moulin C; de Azambuja E; Ahmad A
Expert Opin Investig Drugs; 2009 Aug; 18(8):1183-9. PubMed ID: 19604119
[TBL] [Abstract][Full Text] [Related]
33. [A case of irreversible cardiomyopathy induced by polychemotherapy].
Skopets IS; Vezikova NN; Ivanova EP; Sergeeva SS; Ignatenko OV
Ter Arkh; 2015; 87(12):73-76. PubMed ID: 26978422
[TBL] [Abstract][Full Text] [Related]
34. Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer.
Peters-Engl C; Cassik P; Schmidt I; Denison U; Medl M; Pokieser W; Sevelda P
Acta Oncol; 2005; 44(2):129-33. PubMed ID: 15788291
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
Man M; Rugo H
IDrugs; 2005 Sep; 8(9):739-54. PubMed ID: 16118697
[TBL] [Abstract][Full Text] [Related]
36. Recurrent ovarian cancer.
Tummala MK; McGuire WP
Clin Adv Hematol Oncol; 2005 Sep; 3(9):723-36. PubMed ID: 16224447
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
Battaglia A; Bernacki RJ; Bertucci C; Bombardelli E; Cimitan S; Ferlini C; Fontana G; Guerrini A; Riva A
J Med Chem; 2003 Nov; 46(23):4822-5. PubMed ID: 14584931
[TBL] [Abstract][Full Text] [Related]
38. Second generation taxanes: from the natural framework to the challenge of drug resistance.
Ferlini C; Ojima I; Distefano M; Gallo D; Riva A; Morazzoni P; Bombardelli E; Mancuso S; Scambia G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):133-8. PubMed ID: 12678907
[TBL] [Abstract][Full Text] [Related]
39. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
McWhinney-Glass S; Winham SJ; Hertz DL; Yen Revollo J; Paul J; He Y; Brown R; Motsinger-Reif AA; McLeod HL;
Clin Cancer Res; 2013 Oct; 19(20):5769-76. PubMed ID: 23963862
[TBL] [Abstract][Full Text] [Related]
40. [Extra- and paravasation of cytotoxic drugs. Pathomechanisms and current preventive measures].
Lipp HP
Med Monatsschr Pharm; 2010 Mar; 33(3):87-94; quiz 95-6. PubMed ID: 20355670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
